Edition:
India

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.92USD
20 Jun 2018
Change (% chg)

$-0.05 (-2.54%)
Prev Close
$1.97
Open
$1.98
Day's High
$2.00
Day's Low
$1.91
Volume
281,623
Avg. Vol
450,804
52-wk High
$6.96
52-wk Low
$1.09

Chart for

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 3.00
Market Cap(Mil.): $526.55
Shares Outstanding(Mil.): 104.68
Dividend: --
Yield (%): --

Financials

BRIEF-Mannkind Q1 Loss Per Share $0.25

* Q1 REVENUE ROSE 15 PERCENT TO $3.4 MILLION Source text for Eikon: Further company coverage:

10 May 2018

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

09 May 2018

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

09 May 2018

BRIEF-Mannkind Announces $28.0 Million Registered Direct Offering

* MANNKIND ANNOUNCES $28.0 MILLION REGISTERED DIRECT OFFERING

06 Apr 2018

BRIEF-MannKind Restructures $79.7 Mln Debt Obligation To The Mann Group

* MANNKIND RESTRUCTURES $79.7 MILLION DEBT OBLIGATION TO THE MANN GROUP AND REDUCES PRINCIPAL OWED TO DEERFIELD BY $6.3 MILLION

12 Mar 2018

BRIEF-Mannkind Corporation Q4 Loss Per Share $0.28

* ORATION REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

28 Feb 2018

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES​ Source text for Eikon: Further company coverage:

06 Feb 2018

BRIEF-Mannkind, On Jan 18, Co, Unit Entered Into Exchange, Sixth Amendment To Facility Agreement With Deerfield

* MANNKIND - ‍ ON JAN 18, CO AND UNIT ENTERED INTO AN EXCHANGE AND SIXTH AMENDMENT TO FACILITY AGREEMENT WITH DEERFIELD - SEC FILING​

19 Jan 2018

Competitors

Earnings vs. Estimates